LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma’s drug NERLYNX in South Korea.
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma’s drug NERLYNX in South Korea.
Copyright © 2023 Biotech Networks, LLC